↧
Image may be NSFW.
Clik here to view.
Clik here to view.
In conversation with Bing Yao
Bing Yao As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Advaxis readies cervical cancer pivotal trial
Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. Daniel O’Connor “We...
View Article